Fundraising Fox

WRF Capital

Corporate VC

Seattle · Pre-Seed–Series B · 21 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

WRF Capital invests roughly $5 million annually in Washington-based startups, focusing on spinouts from state nonprofit research institutions such as UW, WSU, Fred Hutch and ISB. It backs pre-seed through Series A companies across life sciences and enabling technologies, with initial checks of $100,000 to $2 million and reserves for follow-ons. Often the first money in, the firm partners with angels and VCs across rounds and can lead investments, syndicating with value-adding firms. It emphasizes rigorous due diligence and selective investing to help commercialize new technologies developed in Washington.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Series B
Check
$100K – $2M
HQ
Seattle, Washington, US
Leads rounds
Leads
Instruments
Equity
Founded
1996
Last 12 months
1 investment
AUM
$40M
Tracked investments
9

Team · 21 people

from the firm's website & curated
Lisa Caldwell· Executive Assistant

What they invest in

from 6 of 9 portfolio companies

Biotech ×4EdTech ×2Healthtech ×2AI & Machine Learning ×1Deep Tech ×1

HQs:United States×6

Investments · 9 tracked

founders shown can be your intro path

By year:2026 · 12024 · 12015 · 13 dated

Accipiter Biosciencesaccipiterbio.cominJul 2026

Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.

AI & Machine LearningBiotechDeep TechSeattle, US

Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)Hector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)

Co-investorsArgonautic VenturesColumbus Venture PartnersPack Ventures

AnswerDashanswerdash.cominAug 2015

Seattle, US

JACOB O. WOBBROCK(Executive Officer)WILLIAM T. COLLERAN(Executive Officer, Director)ANDREW KO(Executive Officer)

BoardWILLIAM MCALEER(Director)inMARK UPSON(Director)MICHAEL FRIDGEN(Director)

Co-investorsCowles VenturesThe W FundVoyager Capital

BirchAIbirch.aiin

Automates complex call center operations; acquired by Sagility Health.

Co-investorsAllen Institute for AI (AI2) IncubatorFlare Capital PartnersRadical Ventures

Fred Hutchfredhutch.orgin𝕏

Fred Hutch is a cancer treatment and research organization providing patient care, clinical trials, and research into the prevention, early detection, and treatment of cancer, HIV, and other diseases.

BiotechHealthtech

ISBsystemsbiology.orgin𝕏

The Institute for Systems Biology (ISB) is a research organization focused on systems biology science and education, including curriculum development, educator engagement, and student research programs.

Biotech

Pronirasproniras.comFeb 2024

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.

BiotechHealthtechSeattle, US

CHRISTOPHER TOOMBS(Executive Officer)LINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)

BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)

Co-investorsACCELERATOR LIFE SCIENCE PARTNERSARCH Venture Partners

Resolve Therapeuticsresolvetherapeutics.com

Biopharma company developing non-immunosuppressive drugs for autoimmune diseases.

Co-investorsNew Science VenturesEaston Capital

UWwashington.eduin𝕏

The University of Washington is a public university offering education and research across disciplines including oceanography, business, bioengineering, AI, pharmacy, arts, humanities, and natural and social sciences.

EdTechSeattle, US

Co-investorsShumo Chu

WSUwsu.edu

Washington State University is a public research university offering hundreds of degree programs across six campuses, with research and extension operations throughout Washington state.

EdTech

Portfolio news

latest coverage across their companies

Frequently asked questions

What stage does WRF Capital invest at?
WRF Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
What is WRF Capital's typical check size?
WRF Capital typically writes checks of $100K – $2M.
What sectors does WRF Capital focus on?
WRF Capital focuses on Biotech, Consumer, Data & Infrastructure, Deep Tech, Digital Health, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, SaaS.
Where is WRF Capital located?
WRF Capital is headquartered in Seattle, US.
Does WRF Capital lead rounds?
Yes, WRF Capital leads investment rounds.

Co-investors · 1

Ambit Health Ventures

Early-stage venture capital firm focused on digital health innovations including digital diagnostics, digital therapeutics, and tech-enabled services. Based in Boston and Philadelphia with deep clinical expertise and experience building and scaling healthcare ventures.

Firms observed investing alongside WRF Capital, from public investor directories. Shared companies are the overlap with WRF Capital's recorded portfolio.

Similar investors

Featured in lists